Drug intelligence / Profile preview

Ambrax

Development stage: Unknown
Lead developer: Homviora Arzneimittel Dr. Hagedorn
Administration: Oral

Overview

Ambrax is a homeopathic complex preparation manufactured by the German company HOMVIORA. It is indicated for the treatment of nervous disorders, including states of exhaustion, sleep disturbances, and functional heart complaints (nervous heart). The product is formulated as oral drops containing a combination of homeopathic dilutions: Ambra grisea (ambergris), Ignatia (Strychnos ignatii), Moschus (musk), and Sepia (cuttlefish ink). As a homeopathic remedy, it is designed to stimulate the body's self-regulatory mechanisms according to traditional homeopathic principles.

Brand names: Ambrax

Beyond the preview

Go deeper on Ambrax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambrax.

Explore the full profile